We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

No Cancer Risk for Telomerase Gene Therapy

News   Aug 21, 2018 | Original Press Release from the CNIO

 
No Cancer Risk for Telomerase Gene Therapy

Representative images of lungs treated with gene therapy vectors. The nuclei are in blue, alveolar type II cells in green and telomeres in red. Notice that lung cells treated with active telomerase present more intense telomeres indicating that they are longer as compared to lung cells treated with the null vectors or with an inactive telomerase. Credit: CNIO

 
 
 

RELATED ARTICLES

Epigenetic Signature May Help People Stay Ahead of IBD

News

In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.

READ MORE

Decoding the Structure of an RNA-Based CRISPR System

News

Over the past several years, CRISPR-Cas9 has moved beyond the lab bench and into the public zeitgeist. Now, scientists from the Salk Institute are reporting for the first time the detailed molecular structure of CRISPR-Cas13d, a promising enzyme for emerging RNA-editing technology.

READ MORE

Unprecedented View of Gene Therapy Virus

News

Using cryo-electron microscopy, scientists have obtained an unprecedented view of a gene-delivery virus, paving the way for further development of improved gene therapies.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE